Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis

Open access

Abstract

Pirfenidone is one of two approved therapies for the treatment of idiopathic pulmonary fibrosis (IPF). Randomised controlled clinical trials and subsequent post hoc analyses have demonstrated that pirfenidone reduces lung function decline, decreases mortality and improves progression-free survival. Long-term extension trials, registries and real-world studies have also shown similar treatment effects with pirfenidone. However, for patients with IPF to obtain the maximum benefits of pirfenidone treatment, the potential adverse events (AEs) associated with pirfenidone need to be managed. This review highlights the well-known and established safety profile of pirfenidone based on randomised controlled clinical trials and real-world data. Key strategies for preventing and managing the most common pirfenidone-related AEs are described, with the goal of maximising adherence to pirfenidone with minimal AEs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/16000617.0057-2017

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Kaplan–Meier analysis of time to first occurrence of a pirfenidone-related adverse event (AE) as measured from randomisation, irrespective of treatment duration, in the pooled phase III clinical trials. GI: gastrointestinal. #: includes all AEs of nausea; these AEs are also included in the group “GI disorders”.
FIGURE 1 Kaplan–Meier analysis of time to first occurrence of a pirfenidone-related adverse event (AE) as measured from randomisation, irrespective of treatment duration, in the pooled phase III clinical trials. GI: gastrointestinal. #: includes all AEs of nausea; these AEs are also included in the group “GI disorders”.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Research works printed but not linked: 4

  1. Lancaster, 2016, Safety of pirfenidone in patients with idiopathic pulmonary fibrosis in a US expanded access program, Am J Respir Crit Care Med, 193, A2695
  2. Mason, 2017, Time-to-event analysis of common adverse events with pirfenidone in patients with IPF – a pooled analysis of three phase III clinical trials, Am J Respir Crit Care Med, 195, A6798
  3. Lancaster, 2017, Pirfenidone in patients aged 80 years and older with idiopathic pulmonary fibrosis (IPF): safety findings from pooled trial databases, Am J Respir Crit Care Med, 195, A5385
  4. Glassberg, 2016, Cardiovascular events in phase 3 trials of pirfenidone in idiopathic pulmonary fibrosis (IPF), Am J Respir Crit Care Med, 193, A4980

Cited by

See all 322

Metadata

Authors
Lancaster, L. H., de Andrade, J. A., Zibrak, J. D., Padilla, M. L., Albera, C., Nathan, S. D., Wijsenbeek, M. S., Stauffer, J. L., Kirchgaessler, K.-U., & Costabel, U.
Affiliations
  • Vanderbilt University Medical Center (US)
  • Beth Israel Deaconess Medical Center (US)
  • University of Turin (IT)
  • Inova Fairfax Hospital (US)
  • Erasmus MC (NL)
  • Genentech (US)
  • F. Hoffmann-La Roche AG (CH)
  • Ruhrlandklinik (DE)
Corresponding author
Lancaster, Lisa H.
Venue
European Respiratory Review
Published
2017-12-06
Volume
26
Issue
146
Pages
170057
ISSN
  • 0905-9180 (ISSN-L)
  • 1600-0617
OpenAlex
W2774138788
Cited by
295
References
52
Citations by year
2026: 36 · 2025: 45 · 2024: 36 · 2023: 50 · 2022: 35 · 2021: 29 · 2020: 38 · 2019: 17 · 2018: 9
FWCI
3.19
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • European Respiratory Review (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
Funders
  • GlaxoSmithKline
  • Gilead Sciences
  • Biogen
  • Celgene
  • FibroGen
  • F. Hoffmann-La Roche
  • Veracyte
  • National Institutes of Health
  • Genentech
  • National Heart, Lung, and Blood Institute
  • UCB Celltech
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Keywords
pirfenidone, idiopathic pulmonary fibrosis, drug safety, adverse events, adverse event management, medication adherence, lung function decline, real-world data
MeSH terms
Anti-Inflammatory Agents, Non-Steroidal, Humans, Lung, Pyridones, Risk Factors, Time Factors, Treatment Outcome, Disease-Free Survival, Recovery of Function, Idiopathic Pulmonary Fibrosis, Medication Adherence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. https://app.cochat.ai/papers/10.1183/16000617.0057-2017
The paper
Lancaster, L. H., de Andrade, J. A., Zibrak, J. D., Padilla, M. L., Albera, C., Nathan, S. D., Wijsenbeek, M. S., Stauffer, J. L., Kirchgaessler, K.-U., & Costabel, U. (2017). Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. European Respiratory Review. https://doi.org/10.1183/16000617.0057-2017

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.